Corporate & Investor Presentation
Unlocking markets and expanding access with
evidence and advocacy
Diverse evidence
generating capabilities
Established
scientific leader
Solid foundation
of clinical trials
Economics
and outcomes
for value-
based
decisions
ResMed
Evidence
Generation Team
Behavior
and
population
health
research
1KOLs: Key opinion leaders
Real world
evidence studies
with KOLs1
1,096
# of publications from
1996 onward
484
269
Better access
and advocacy
Unlocking reimbursement
•
U.S. Competitive Bidding Program delay and
removal of NIV from the program
Supporting the creation of new U.S. physician.
remote monitoring codes
• On-time device reimbursement in key markets
Thought leadership
•
Achieved leadership positions in key global
MedTech associations
Thought leader in European and member state
health data policy and remote monitoring
reimbursement conversations
ResMed
Peer 1
Peer 2
Strong history of market development and growth
Engagement on key policies
Health Technology Assessments
(e.g., UK NICE)
Analyses of French health insurance data to
demonstrate the positive impact of CPAP
therapy on lowering mortality rates
7 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22
ResMedView entire presentation